In-Depth Comparison of Dry Particle Coating Processes Used in DPI Particle Engineering.

adhesion strength compound excipient dry powder inhalation force control agent surface energy

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
19 Apr 2021
Historique:
received: 18 03 2021
revised: 08 04 2021
accepted: 16 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 1 5 2021
Statut: epublish

Résumé

High-shear mixer coatings as well as mechanofusion processes are used in the particle-engineering of dry powder inhalation carrier systems. The aim of coating the carrier particle is usually to decrease carrier-drug adhesion. This study comprises the in-depth comparison of two established dry particle coating options. Both processes were conducted with and without a model additive (magnesium stearate). In doing so, changes in the behaviour of the processed particles can be traced back to either the process or the additive. It can be stated that the coarse model carrier showed no significant changes when processed without additives. By coating the particles with magnesium stearate, the surface energy decreased significantly. This leads to a significant enhancement of the aerodynamic performance of the respective carrier-based blends. Comparing the engineered carriers with each other, the high-shear mixer coating shows significant benefits, namely, lower drug-carrier adhesion and the higher efficiency of the coating process.

Identifiants

pubmed: 33921741
pii: pharmaceutics13040580
doi: 10.3390/pharmaceutics13040580
pmc: PMC8073608
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Int J Pharm. 2008 Feb 4;348(1-2):10-7
pubmed: 17689898
Pharm Res. 2006 Aug;23(8):1665-74
pubmed: 16845584
AAPS PharmSciTech. 2013 Mar;14(1):38-44
pubmed: 23196863
Int J Pharm. 2010 Jan 4;383(1-2):62-9
pubmed: 19748561
Langmuir. 2008 Sep 2;24(17):9551-7
pubmed: 18680326
J Pharm Sci. 2018 Apr;107(4):984-998
pubmed: 29247741
J Pharm Pharmacol. 2012 Sep;64(9):1337-48
pubmed: 22881445
Chem Pharm Bull (Tokyo). 2006 Nov;54(11):1508-14
pubmed: 17077547
Int J Pharm. 2020 Aug 30;586:119592
pubmed: 32622814
Int J Pharm. 2020 Sep 25;587:119666
pubmed: 32702450
Curr Pharm Des. 2015;21(19):2677-94
pubmed: 25876912
Expert Opin Drug Deliv. 2017 Apr;14(4):499-512
pubmed: 27534768
Lancet Respir Med. 2020 Jun;8(6):531-533
pubmed: 32526184
Eur J Pharm Sci. 2011 Jul 17;43(4):325-33
pubmed: 21621612
Int J Pharm. 2016 Dec 5;514(2):374-383
pubmed: 27262269

Auteurs

Nicholas Bungert (N)

Department of Pharmaceutics and Biopharmaceutics, Kiel University, Grasweg 9a, 24118 Kiel, Germany.

Mirjam Kobler (M)

Meggle Excipients and Technology, 83512 Wasserburg, Germany.

Regina Scherließ (R)

Department of Pharmaceutics and Biopharmaceutics, Kiel University, Grasweg 9a, 24118 Kiel, Germany.

Classifications MeSH